Selective Inhibition of Human Lung Cancer Cell Growth by Peptides Derived from Retinoblastoma Protein

Peptides containing retinoblastoma protein (RB) fragment 649-654 (LFYKKV) were tested for their ability to block the proliferation of RB-negative and RB-positive human non-small cell lung cancer (NSCLC) cells. These peptides potently restrained the growth of both types of tumor cells, as measured by...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2000-01, Vol.267 (1), p.71-76
Main Authors: Radulescu, Razvan T., Jaques, Gabriele
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Carcinoma, Non-Small-Cell Lung - pathology
Cell Division - drug effects
Cell Survival - drug effects
Dose-Response Relationship, Drug
Genes, Retinoblastoma
Humans
lung carcinoma
Lung Neoplasms - pathology
Lymphocytes - cytology
Lymphocytes - drug effects
Molecular Sequence Data
Peptide Fragments - chemistry
Peptide Fragments - pharmacology
Rb protein
Retinoblastoma Protein - chemistry
Retinoblastoma Protein - pharmacology
Tumor Cells, Cultured
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peptides containing retinoblastoma protein (RB) fragment 649-654 (LFYKKV) were tested for their ability to block the proliferation of RB-negative and RB-positive human non-small cell lung cancer (NSCLC) cells. These peptides potently restrained the growth of both types of tumor cells, as measured by metabolic (MTT) and cellular viability (trypan blue exclusion) assays. As such, and remarkably, the peptides were able to overcome the resistance of RB-positive cells usually observed with RB gene or protein replacement therapy. Compared to the overall performance of conventional chemotherapy tested in parallel, the peptides were more cytotoxic against RB-negative neoplastic cells and equipotent toward RB-positive tumor cells, yet less toxic toward normal human cells. Thus, these new molecules hold great promise to evolve into an efficient therapy for human lung cancer, a common malignancy still defying treatment and holding a poor prognosis, as well as for other human neoplasias.
ISSN:0006-291X
1090-2104
DOI:10.1006/bbrc.1999.1902